Eupraxia Pharmaceuticals Reports Positive Treatment Outcomes in Eosinophilic Esophagitis Trial

Eupraxia Pharmaceuticals announced sustained positive treatment outcomes in patients with eosinophilic esophagitis (EoE) after nine months of receiving EP-104GI. Patients who received 48mg of EP-104GI experienced sustained or improved treatment outcomes. The company plans to release additional long-term data with higher doses in Q3 2025 and will host a webinar with Dr. Evan Dellon on May 9th to discuss data from the RESOLVE trial.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has announced sustained positive treatment outcomes from its RESOLVE Phase 1b/2a trial of EP-104GI for eosinophilic esophagitis (EoE). The company reported that all patients who received 48mg of EP-104GI experienced sustained or improved treatment outcomes after nine months. Key findings include a significant reduction in symptom severity, tissue health, and eosinophil counts.

The trial, which is evaluating EP-104GI across multiple patient cohorts, showed that after 9 months, patients receiving 48mg of EP-104GI experienced a 100% reduction in symptom severity in some cases, with an average 65% improvement in Straumann Dysphagia Index (SDI) scores. Additionally, there was a 56% reduction in tissue health (EoEHSS Stage) and a 45% reduction in Grade score. Eosinophil counts decreased by 77% on average, with a 52% remission rate. Notably, one patient maintained complete histologic remission from 3 through 9 months.

Eupraxia plans to release additional long-term data with higher doses in Q3 2025. The company will also host a webinar on May 9th with Dr. Evan Dellon to discuss the data from the RESOLVE trial [1].

EoE is an inflammatory-mediated disease affecting more than 450,000 people in the United States, according to market research from Clearview Healthcare Partners. The condition is characterized by the migration of white blood cells into and becoming trapped in the esophagus, causing pain and difficulty swallowing food. The RESOLVE trial is a Phase 1b/2a, multicenter, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with histologically confirmed active EoE [2].

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products for therapeutic areas with high unmet medical need. The company's proprietary DiffuSphere™ technology aims to optimize drug delivery, potentially reducing adverse events and improving efficacy and duration of effect [3].

References:
[1] https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-announces-sustained-positive-treatment-tv434seulu9p.html
[2] https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-announces-sustained-positive-treatment-tv434seulu9p.html
[3] https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-announces-sustained-positive-treatment-tv434seulu9p.html